Shore, N. D., Gleave, M., Giorgi, U. D., Rannikko, A., Sridharan, S., Brasso, K., Woo, H. H., Caamaño, A. G., Nordquist, L., Tang, Y., Croitoru, R., Rosales, M., Kalac, M., Peraud, O., Wang, F., Freedland, S. J. (2025). Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) plus leuprolide (combo): EMBARK post hoc analysis.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.e17127